Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance

Virology

Volumn 435, Issue 2, 2013, Pages 433-441

  Delviks Frankenberry, Krista A ^a   Lengruber, Renan B ^b   Santos, Andre F ^b   Silveira, Jussara M ^c   Soares, Marcelo A ^b,d   Kearney, Mary F ^a   Maldarelli, Frank ^a   Pathak, Vinay K ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Connection domain; Drug resistance; NNRTI; NRTI; Subtype C

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; BRAZIL; CLINICAL ARTICLE; CONNECTION SUBDOMAIN; CONTROLLED STUDY; DRUG RESPONSE; EMBRYO; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE C; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BRAZIL; CELL LINE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN STRUCTURE, TERTIARY; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84871689980     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.09.021     Document Type: Article

References (65)

1. Abecasis A.B., Deforche K., Snoeck J., Bacheler L.T., McKenna P., Carvalho A.P., Gomes P., Camacho R.J., Vandamme A.M. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005, 19:1799-1806.
2. Alexander C.S., Montessori V., Wynhoven B., Dong W., Chan K., O'Shaughnessy M.V., Mo T., Piaseczny M., Montaner J.S., Harrigan P.R. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir. Ther. 2002, 7:31-35.
3. Boyer P.L., Sarafianos S.G., Arnold E., Hughes S.H. The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J. Virol. 2002, 76:3248-3256.
4. Brehm J.H., Koontz D.L., Wallis C.L., Shutt K.A., Sanne I., Wood R., McIntyre J.A., Stevens W.S., Sluis-Cremer N., Mellors J.W. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse transcriptase inhibitors. Clin. Infect. Dis. 2012, 5:737-745.
5. Brehm J.H., Lalama C.M., Hughes M.D., Haubrich R., Riddler S.A., Sluis-Cremer N., Mellors J.W. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase. J. Acquir. Immune Defic. Syndr. 2011, 56:344-348.
6. Brehm J.H., Scott Y., Koontz D.L., Perry S., Hammer S., Katzenstein D., Mellors J.W., Sluis-Cremer N. Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase. PLoS One 2012, 7:e31558.
7. Brenner B., Turner D., Oliveira M., Moisi D., Detorio M., Carobene M., Marlink R.G., Schapiro J., Roger M., Wainberg M.A. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003, 17:F1-F5.
8. Brenner B.G., Oliveira M., Doualla-Bell F., Moisi D.D., Ntemgwa M., Frankel F., Essex M., Wainberg M.A. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006, 20:F9-F13.
9. Cane P.A., Green H., Fearnhill E., Dunn D. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 2007, 21:447-455.
10. Caride E., Hertogs K., Larder B., Dehertogh P., Brindeiro R., Machado E., de Sa C.A., Eyer-Silva W.A., Sion F.S., Passioni L.F., Menezes J.A., Calazans A.R., Tanuri A. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes 2001, 23:193-202.
11. Dau B., Ayers D., Singer J., Harrigan P.R., Brown S., Kyriakides T., Cameron D.W., Angus B., Holodniy M. Connection domain mutations in treatment-experienced patients in the OPTIMA trial. J. Acquir. Immune Defic. Syndr. 2010, 54:160-166.
12. Delviks-Frankenberry K.A., Nikolenko G.N., Boyer P.L., Hughes S.H., Coffin J.M., Jere A., Pathak V.K. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc. Natl. Acad. Sci. U.S.A 2008, 105:10943-10948.
13. Delviks-Frankenberry K.A., Nikolenko G.N., Maldarelli F., Hase S., Takebe Y., Pathak V.K. Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine. J. Virol. 2009, 83:8502-8513.
14. Delviks-Frankenberry K.A., Nikolenko G.N., Pathak V.K. The "connection" between HIV drug resistance and RNase H. Viruses 2010, 2:1476-1503.
15. di Marzo Veronese F., Copeland T.D., DeVico A.L., Rahman R., Oroszlan S., Gallo R.C., Sarngadharan M.G. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 1986, 231:1289-1291.
16. Ehteshami M., Beilhartz G.L., Scarth B.J., Tchesnokov E.P., McCormick S., Wynhoven B., Harrigan P.R., Gotte M. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. J. Biol. Chem. 2008, 283:22222-22232.
17. Frankel F.A., Marchand B., Turner D., Gotte M., Wainberg M.A. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 2005, 49:2657-2664.
18. Frater A.J., Dunn D.T., Beardall A.J., Ariyoshi K., Clarke J.R., McClure M.O., Weber J.N. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002, 16:1139-1146.
19. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., Novitsky V., Haynes B., Hahn B.H., Bhattacharya T., Korber B. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296:2354-2360.
20. Geretti A.M., Harrison L., Green H., Sabin C., Hill T., Fearnhill E., Pillay D., Dunn D. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin. Infect. Dis. 2009, 48:1296-1305.
21. Gotte M., Arion D., Parniak M.A., Wainberg M.A. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. 2000, 74:3579-3585.
22. Grossman Z., Istomin V., Averbuch D., Lorber M., Risenberg K., Levi I., Chowers M., Burke M., Bar Yaacov N., Schapiro J.M. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004, 18:909-915.
23. Gupta S., Fransen S., Paxinos E.E., Stawiski E., Huang W., Petropoulos C.J. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and non-nucleoside reverse transcriptase inhibitor resistance. Antimicrob. Agents Chemother. 2010, 54:1973-1980.
24. Gupta S., Vingerhoets J., Fransen S., Tambuyzer L., Azijn H., Frantzell A., Paredes R., Coakley E., Nijs S., Clotet B., Petropoulos C.J., Schapiro J., Huang W., Picchio G. Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens. Antimicrob. Agents Chemother. 2011, 55:2872-2879.
25. Hachiya A., Kodama E.N., Sarafianos S.G., Schuckmann M.M., Sakagami Y., Matsuoka M., Takiguchi M., Gatanaga H., Oka S. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors. J. Virol. 2008, 82:3261-3270.
26. Hachiya A., Shimane K., Sarafianos S.G., Kodama E.N., Sakagami Y., Negishi F., Koizumi H., Gatanaga H., Matsuoka M., Takiguchi M., Oka S. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients. Antiviral Res. 2009, 82:115-121.
27. Haidara A., Chamberland A., Sylla M., Aboubacrine S.A., Cisse M., Traore H.A., Maiga M.Y., Tounkara A., Nguyen V.K., Tremblay C. High level of primary drug resistance in Mali. HIV Med. 2010, 11:404-411.
28. Hemelaar J., Gouws E., Ghys P.D., Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689.
29. Holguin A., Ramirez de Arellano E., Rivas P., Soriano V. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev. 2006, 8:98-107.
30. Huang W., Gamarnik A., Limoli K., Petropoulos C.J., Whitcomb J.M. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 2003, 77:1512-1523.
31. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., Richman D.D. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010, 18:156-163.
32. Kantor R., Katzenstein D.A., Efron B., Carvalho A.P., Wynhoven B., Cane P., Clarke J., Sirivichayakul S., Soares M.A., Snoeck J., Pillay C., Rudich H., Rodrigues R., Holguin A., Ariyoshi K., Bouzas M.B., Cahn P., Sugiura W., Soriano V., Brigido L.F., Grossman Z., Morris L., Vandamme A.M., Tanuri A., Phanuphak P., Weber J.N., Pillay D., Harrigan P.R., Camacho R., Schapiro J.M., Shafer R.W. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005, 2:e112.
33. Kearney M., Palmer S., Maldarelli F., Shao W., Polis M.A., Mican J., Rock-Kress D., Margolick J.B., Coffin J.M., Mellors J.W. Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 2008, 22:497-501.
34. Lai M.T., Lu M., Felock P.J., Hrin R.C., Wang Y.J., Yan Y., Munshi S., McGaughey G.B., Tynebor R.M., Tucker T.J., Williams T.M., Grobler J.A., Hazuda D.J., McKenna P.M., Miller M.D. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2010, 54:4812-4824.
35. Lengruber R.B., Delviks-Frankenberry K.A., Nikolenko G.N., Baumann J., Santos A.F., Pathak V.K., Soares M.A. Phenotypic charcterization of drug resistance-associated mutations in HIV-RT connection and RNase H domains and their correlation with thymidine analogue mutations. J. Antimicrob. Chem. 2011, 66:702-708.
36. Lowe D.M., Aitken A., Bradley C., Darby G.K., Larder B.A., Powell K.L., Purifoy D.J., Tisdale M., Stammers D.K. HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis. Biochemistry 1988, 27:8884-8889.
37. Martinez-Cajas J.L., Pai N.P., Klein M.B., Wainberg M.A. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J. Int. AIDS Soc. 2009, 12:11.
38. Martinez-Cajas J.L., Pant-Pai N., Klein M.B., Wainberg M.A. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev. 2008, 10:212-223.
39. McCormick A.L., Parry C.M., Crombe A., Goodall R.L., Gupta R.K., Kaleebu P., Kityo C., Chirara M., Towers G.J., Pillay D. Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1. Antimicrob. Agents Chemother. 2011, 55:1806-1809.
40. Michels I., Staszewski S., Gurtler L., Nisius G., Muller A., Locher L., Doerr H.W., Sturmer M. Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment. Eur. J. Med. Res. 2010, 15:415-421.
41. Miranda L.R., Gotte M., Liang F., Kuritzkes D.R. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob. Agents Chemother. 2005, 49:2648-2656.
42. Nikolenko G.N., Delviks-Frankenberry K.A., Palmer S., Maldarelli F., Fivash M.J., Coffin J.M., Pathak V.K. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc. Natl. Acad. Sci. U.S.A 2007, 104:317-322.
43. Nikolenko G.N., Delviks-Frankenberry K.A., Pathak V.K. A novel molecular mechanism of dual resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors. J. Virol. 2010, 84:5238-5249.
44. Nikolenko G.N., Palmer S., Maldarelli F., Mellors J.W., Coffin J.M., Pathak V.K. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. U.S.A 2005, 102:2093-2098.
45. Palmer S., Alaeus A., Albert J., Cox S. Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res. Hum. Retroviruses 1998, 14:157-162.
46. Pillay D., Walker A.S., Gibb D.M., de Rossi A., Kaye S., Ait-Khaled M., Munoz-Fernandez M., Babiker A. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J. Infect. Dis. 2002, 186:617-625.
47. Plantier J.C., Leoz M., Dickerson J.E., De Oliveira F., Cordonnier F., Lemee V., Damond F., Robertson D.L., Simon F. A new human immunodeficiency virus derived from gorillas. Nat. Med. 2009, 15:871-872.
48. Poveda E., de Mendoza C., Pattery T., Gonzalez M.D., Villacian J., Soriano V. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to non-nucleoside analogues. AIDS 2008, 22:2395-2398.
49. Price H., Asboe D., Pozniak A., Gazzard B., Fearnhill E., Pillay D., Dunn D. Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Antivir. Ther. 2010, 15:203-211.
50. Robertson D.L., Anderson J.P., Bradac J.A., Carr J.K., Foley B., Funkhouser R.K., Gao F., Hahn B.H., Kalish M.L., Kuiken C., Learn G.H., Leitner T., McCutchan F., Osmanov S., Peeters M., Pieniazek D., Salminen M., Sharp P.M., Wolinsky S., Korber B. HIV-1 nomenclature proposal. Science 2000, 288:55-56.
51. Saeng-aroon S., Tsuchiya N., Auwanit W., Ayuthaya P.I., Pathipvanich P., Sawanpanyalert P., Rojanawiwat A., Kannagi M., Ariyoshi K., Sugiura W. Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort. Antiviral Res. 2010, 87:22-29.
52. Santos A.F., Lengruber R.B., Soares E.A., Jere A., Sprinz E., Martinez A.M., Silveira J., Sion F.S., Pathak V.K., Soares M.A. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS One 2008, 3:e1781.
53. Santos A.F., Silveira J., Muniz C.P., Tornatore M., Goes L.R., Mendoza-Sassi R.A., Martinez A.M., Tupinambas U., Greco D.B., Soares M.A. Primary HIV-1 drug resistance in the C-terminal domains of viral reverse transcriptase among drug-naive patients from Southern Brazil. J. Clin. Virol. 2011, 52:373-376.
54. Santos A.F., Soares M.A. HIV genetic diversity and drug resistance. Viruses 2010, 2:503-531.
55. Soares E.A., Martinez A.M., Souza T.M., Santos A.F., Da Hora V., Silveira J., Bastos F.I., Tanuri A., Soares M.A. HIV-1 subtype C dissemination in southern Brazil. AIDS 2005, 19:S81-S86.
56. Soares E.A., Santos A.F., Sousa T.M., Sprinz E., Martinez A.M., Silveira J., Tanuri A., Soares M.A. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS One 2007, 2:e730.
57. Soares M.A., De Oliveira T., Brindeiro R.M., Diaz R.S., Sabino E.C., Brigido L., Pires I.L., Morgado M.G., Dantas M.C., Barreira D., Teixeira P.R., Cassol S., Tanuri A. A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil. AIDS 2003, 17:11-21.
58. Tanuma J., Hachiya A., Ishigaki K., Gatanaga H., Lien T.T., Hien N.D., Kinh N.V., Kaku M., Oka S. Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors. Microbes Infect. 2010, 12:1170-1177.
59. Vingerhoets J., Azijn H., Fransen E., De Baere I., Smeulders L., Jochmans D., Andries K., Pauwels R., de Bethune M.P. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 2005, 79:12773-12782.
60. von Wyl V., Ehteshami M., Demeter L.M., Burgisser P., Nijhuis M., Symons J., Yerly S., Boni J., Klimkait T., Schuurman R., Ledergerber B., Gotte M., Gunthard H.F. HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clin. Infect. Dis. 2010, 51:620-628.
61. von Wyl V., Ehteshami M., Symons J., Burgisser P., Nijhuis M., Demeter L.M., Yerly S., Boni J., Klimkait T., Schuurman R., Ledergerber B., Gotte M., Gunthard H.F. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. J. Infect. Dis. 2010, 201:1054-1062.
62. Waters J.M., O'Neal W., White K.L., Wakeford C., Lansdon E.B., Harris J., Svarovskaia E.S., Miller M.D., Borroto-Esoda K. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. Antivir Ther. 2009, 14:231-239.
63. Xu H.T., Quan Y., Asahchop E., Oliveira M., Moisi D., Wainberg M.A. Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C. Retrovirology 2010, 7:80.
64. Yap S.H., Sheen C.W., Fahey J., Zanin M., Tyssen D., Lima V.D., Wynhoven B., Kuiper M., Sluis-Cremer N., Harrigan P.R., Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. Plos Med. 2007, 4:1887-1900.
65. Yee J.K., Miyanohara A., LaPorte P., Bouic K., Burns J.C., Friedmann T. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. U.S.A 1994, 91:9564-9568.